Abstract:Abstract Background: Incorporation of molecular biomarkers and histological features could be applicated for more-precise tumour categorization and individualized treatment. IDH1/2 mutations, 1p/19q co-deletion and TERT-promoter mutations were requisite diagnostic biomarkers for gliomas classification. BRAF V600E mutation was common in a wide spectrum of brain tumors, including gliomas and glioneuronal tumors. Currently, FISH is the gold standard method for detecting 1p/19q co-deletion and qPCR was often used to detect hotspot mutations. However, all five genetic biomarkers couldn't be evaluated with same system. Here, we developed an all-in-one panel for brain cancer based on amplicon sequencing, which could detect all five biomarkers simultaneously. Methods: 155 specimens were collected from glioma patients in China. To evaluate the accuracy of five biomarkers panel (Genetron health), every specimen was analyzed by both five biomarkers panel and the combination method, which included qPCR analysis of hotspot mutations (IDH1 R132H/C, IDH2 R172K, TERT promoter C228T/C250T and BRAF V600E) and FISH analysis of 1p/19q co-deletion. For five biomarkers panel, DNA fragments containing hotspot mutations in four genes and 59 single-nucleotide polymorphisms (SNPs) in chromosome 1p/19q were amplified and the library was constructed. Sequencing was performed on Ion GeneStudio S5 system. The reads mapping, mutations calling and 1p/19q deletion calling were handled by in-house bioinformatic workflow. Results: Comparing performance of hotspot mutations detection, we found that five biomarkers panel was very consistent with qPCR but only in one specimen, in which BRAF V600E was detected by five biomarkers panel but not qPCR. For 1p/19q co-deletion analysis, 96% (149/155) of specimens were consistent. Only 1p deletion was identified by FISH in 2 specimens, in which 1p/19q co-deletion were identified by five biomarkers panel. In 2 specimens, 1p deletion or 19q deletion was detected by five biomarkers panel, but no deletion was detected by FISH. In the other 2 specimens, 1p deletion or 19q deletion could be detected by FISH, but not by 5 biomarkers panel. Furthermore, for multi-system combination analysis, each specimen was needed for DNA extraction and FISH slide preparation. Comparing to 10 ng DNA, which was enough for analysis by five biomarkers panel for brain cancer, much more FFPE orfresh frozen tumor tissues were required for multi-system combination method analysis. Conclusions: Glioma 5 biomarker panel, by which hotspot mutations of IDH1/IDH2, TERT promoter, BRAF and 1p/19q co-deletion can be detected with same high-throughput sequencing platform and analysis pipeline, required less biopsy and was highly consistent with current technologies such as qPCR and FISH. Citation Format: Min Shi, Sumin Geng, Yanling Niu, Jiao Feng, Xiao Shi, Le Li, Huiming Zhu, Min Chen, Yukun Zhang, Lin Teng, Qiaosong Zheng, Tonghui Ma. An amplicon sequencing based all-in-one genetic testing panel for molecular classification and guiding individualized treatment of brain cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 743.

BIOM-54. A RAPID GENOTYPING PANEL FOR SENSITIVE AND SPECIFIC SEGREGATION OF CNS PATHOLOGIES

Rapid Tumor DNA Analysis of Cerebrospinal Fluid Accelerates Treatment of Central Nervous System Lymphoma

Targeted multiplex validation of CSF proteomic biomarkers: implications for differentiation of PCNSL from tumor-free controls and other brain tumors

Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors

Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL

Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers

BIOM-65. NEW BIOMARKERS FOR THE DIAGNOSIS OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN CEREBROSPINAL FLUID: AN EXPLORATORY MULTICENTER RETROSPECTIVE COHORT STUDY

Biom-28. Whole Exome Tumor Molecular Profiling From Cerebrospinal Fluid (Csf): Preliminary Results Of A Pilot Study

BIOM-24. TARGETED NEXT-GENERATION SEQUENCING (NGS) OF TEMPORALLY MATCHED CEREBROSPINAL FLUID (CSF) AND TUMOR TISSUE IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

ML-06 Diagnostic value of liquid biopsy for CNS lymphoma by detection of specific gene mutations in the cerebrospinal fluid

Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma

Abstract 2421: Targeted and low-pass whole genome sequencing of cerebrospinal fluid circulating tumor DNA for the diagnosis and monitoring of pediatric, adolescent and young adult CNS tumors

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas

Cnsc-58. Bioprocessing Of Viable Surgical Pediatric Brain Tumor Specimens For Genome-Guided Personalized Drug Testing

Abstract 743: An amplicon sequencing based all-in-one genetic testing panel for molecular classification and guiding individualized treatment of brain cancer

Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAM

High-throughput quantitation of amino acids and acylcarnitine in cerebrospinal fluid: identification of PCNSL biomarkers and potential metabolic messengers

Rapid Intraoperative Amplicon Sequencing of CNS Tumor Markers

ML-7 Liquid biopsy for MYD88 mutation in cerebrospinal fluid in patients with suspected primary CNS lymphoma

JS08.6.A CSF DERIVED LIQUID BIOPSIES FOR GLIOMA DIAGNOSIS

The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid